Cerebral cavernous malformation (CCM), also knows a cavernous hemangioma, cavernous angioma or cavernoma, is a brain blood vessel malformation characterized by irregularly clustered small thin-walled ...

BOSTON--(BUSINESS WIRE)--BioAxone BioSciences, Inc., a biotechnology company committed to discovering and developing drugs for unmet needs of neurological conditions today announced the license of ...

Researchers have uncovered new details about the relationship between two proteins associated with the formation of cerebral cavernous malformations, a little understood neurovascular disorder. The ...

Cavernous malformations (CMs) are vascular anomalies composed of clusters of dilated, thin-walled capillaries that occur within the central nervous system. These lesions may be asymptomatic or present ...

SALT LAKE CITY, June 13, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the full ...

BOSTON--(BUSINESS WIRE)--Please replace the release with the following corrected version due to revisions. The corrected release reads: BIOAXONE BIOSCIENCES EXPANDS ...

A drug treatment has been proven to prevent lesions from cerebral cavernous malformation -- a brain blood vessel abnormality that can cause bleeding, epilepsy and stroke -- for the first time in a new ...

Recursion announced the results from its Phase 2 SYCAMORE trial of REC-994, a treatment for Cerebral Cavernous Malformations (CCM), at the International Stroke Conference. The trial met its primary ...

Researchers have recently uncovered a new gene mutation responsible for the non-familial patients of cerebral cavernous malformation (CCM) -- a brain vascular disorder which inflicted about 10-30 ...

Neurelis, Inc., today announced it will present at the Alliance to Cure Cavernous Malformation (CCM) 21st International CCM ...

SAN DIEGO, Calif., March 24, 2023 /PRNewswire/ -- Neurelis, Inc., announced the first two cohorts dosed in the investigational clinical trial of NRL-1049, a Rho kinase (ROCK) inhibitor, a potential ...